Blood- and urinary levels of different carnitine-esters during administration of oxaliplatin based chemotherapy
- Conditions
- Carnitine metabolism and carnitine deficiëncyInteraction of oxaliplatin chemotherapy with carnitineChemotherapy induced peripheral neuropathy
- Registration Number
- NL-OMON21217
- Lead Sponsor
- Máxima Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 10
Inclusion Criteria
1. Written informed consent
2. Age >18 years
Exclusion Criteria
1. Patients with known primary carnitine deficiency (congenital)
2. Patients on haemodialysis or peritoneal dialysis
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method -To evaluate the course of plasma- and urinary carnitine levels of all carnitine esters during the first cycle of treatment with oxaliplatin-based chemotherapy: <br /><br>Plasma and urinary concentrations of different carnitine-esters before, during and right after administration of oxaliplatin-based chemotherapy
- Secondary Outcome Measures
Name Time Method -To gain insight in patient factors such as lifestyle, diet and comorbidities that can influence baseline carnitine levels in cancer patients: <br /><br>Length and body weight, information about diet, nicotine- and alcohol consumption habits, comorbidities, type of cancer, cancer stage, chemotherapy regimen, history of chemotherapy use.